A new pharmacological treatment for intermittent claudication

Results of a randomized, multicenter trial

Hugh G. Beebe, David L Dawson, Bruce S. Cutler, J. Alan Herd, D. Eugene Strandness, Enoch B. Bortey, William P. Forbes

Research output: Contribution to journalArticle

266 Citations (Scopus)

Abstract

Background: Effective medication is limited for the relief of intermittent claudication, a common manifestation of arterial occlusive disease. Cilostazol is a potent inhibitor of platelet aggregation with vasodilation effects. Objective: To evaluate the safety and efficacy of cilostazol for the treatment of intermittent claudication. Methods: Thirty- seven outpatient vascular medicine clinics at regional tertiary and university hospitals in the United States participated in this multicenter, randomized, double-blind, placebo-controlled, parallel trial. Of the 663 screened volunteer patients with leg discomfort, a total of 516 men and women 40 years or older with a diagnosis of moderately severe chronic, stable, symptomatic intermittent claudication were randomized to receive cilostazol, 100 mg, cilostazol, 50 mg, or placebo twice a day orally for 24 weeks. Outcome measures included pain-free and maximal walking distances via treadmill testing, patient-based quality-of-life measures, global assessments by patient and physician, and cardiovascular morbidity and all-cause mortality survival analysis. Results: The clinical and statistical superiority of active treatment over placebo was evident as early as week 4, with continued improvement at all subsequent time points. After 24 weeks, patients who received cilostazol, 100 mg, twice a day had a 51% geometric mean improvement in maximal walking distance (P<.001 vs placebo); those who received cilostazol, 50 mg, twice a day had a 38% geometric mean improvement in maximal walking distance (P<.001 vs placebo). These percentages translate into an arithmetic mean increase in distance walked, from 129.7 m at baseline to 258.8 m at week 24 for the cilostazol, 100 mg, group, and from 131.5 to 198.8 m for the cilostazol, 50 mg, group. Geometric mean change for pain-free walking distance increased by 59% (P<.001) and 48% (P<.001), respectively, in the cilostazol, 100 mg, and cilostazol, 50 mg, groups. These results were corroborated by the results of subjective quality-of-life assessments, functional status, and global evaluations. Headache, abnormal stool samples or diarrhea, dizziness, and palpitations were the most commonly reported potentially drug-related adverse events and were self-limited. A total of 75 patients (14.5%) withdrew because of any adverse event, which was equally distributed between all 3 treatment groups. Similarly, there were no differences between groups in the incidence of combined cardiovascular morbidity or all-cause mortality. Conclusion: Compared with placebo, long- term use of cilostazol, 100 mg or 50 mg, twice a day significantly improves walking distances in patients with intermittent claudication.

Original languageEnglish (US)
Pages (from-to)2041-2050
Number of pages10
JournalArchives of Internal Medicine
Volume159
Issue number17
DOIs
StatePublished - Sep 27 1999
Externally publishedYes

Fingerprint

Intermittent Claudication
Multicenter Studies
Pharmacology
Walking
Placebos
Therapeutics
cilostazol
Quality of Life
Morbidity
Arterial Occlusive Diseases
Mortality
Platelet Aggregation Inhibitors
Dizziness
Survival Analysis
Cardiology
Drug-Related Side Effects and Adverse Reactions
Tertiary Care Centers
Vasodilation
Headache
Volunteers

ASJC Scopus subject areas

  • Internal Medicine

Cite this

A new pharmacological treatment for intermittent claudication : Results of a randomized, multicenter trial. / Beebe, Hugh G.; Dawson, David L; Cutler, Bruce S.; Herd, J. Alan; Strandness, D. Eugene; Bortey, Enoch B.; Forbes, William P.

In: Archives of Internal Medicine, Vol. 159, No. 17, 27.09.1999, p. 2041-2050.

Research output: Contribution to journalArticle

Beebe, Hugh G. ; Dawson, David L ; Cutler, Bruce S. ; Herd, J. Alan ; Strandness, D. Eugene ; Bortey, Enoch B. ; Forbes, William P. / A new pharmacological treatment for intermittent claudication : Results of a randomized, multicenter trial. In: Archives of Internal Medicine. 1999 ; Vol. 159, No. 17. pp. 2041-2050.
@article{ebf562ce35ad48a882f782be1fdebe83,
title = "A new pharmacological treatment for intermittent claudication: Results of a randomized, multicenter trial",
abstract = "Background: Effective medication is limited for the relief of intermittent claudication, a common manifestation of arterial occlusive disease. Cilostazol is a potent inhibitor of platelet aggregation with vasodilation effects. Objective: To evaluate the safety and efficacy of cilostazol for the treatment of intermittent claudication. Methods: Thirty- seven outpatient vascular medicine clinics at regional tertiary and university hospitals in the United States participated in this multicenter, randomized, double-blind, placebo-controlled, parallel trial. Of the 663 screened volunteer patients with leg discomfort, a total of 516 men and women 40 years or older with a diagnosis of moderately severe chronic, stable, symptomatic intermittent claudication were randomized to receive cilostazol, 100 mg, cilostazol, 50 mg, or placebo twice a day orally for 24 weeks. Outcome measures included pain-free and maximal walking distances via treadmill testing, patient-based quality-of-life measures, global assessments by patient and physician, and cardiovascular morbidity and all-cause mortality survival analysis. Results: The clinical and statistical superiority of active treatment over placebo was evident as early as week 4, with continued improvement at all subsequent time points. After 24 weeks, patients who received cilostazol, 100 mg, twice a day had a 51{\%} geometric mean improvement in maximal walking distance (P<.001 vs placebo); those who received cilostazol, 50 mg, twice a day had a 38{\%} geometric mean improvement in maximal walking distance (P<.001 vs placebo). These percentages translate into an arithmetic mean increase in distance walked, from 129.7 m at baseline to 258.8 m at week 24 for the cilostazol, 100 mg, group, and from 131.5 to 198.8 m for the cilostazol, 50 mg, group. Geometric mean change for pain-free walking distance increased by 59{\%} (P<.001) and 48{\%} (P<.001), respectively, in the cilostazol, 100 mg, and cilostazol, 50 mg, groups. These results were corroborated by the results of subjective quality-of-life assessments, functional status, and global evaluations. Headache, abnormal stool samples or diarrhea, dizziness, and palpitations were the most commonly reported potentially drug-related adverse events and were self-limited. A total of 75 patients (14.5{\%}) withdrew because of any adverse event, which was equally distributed between all 3 treatment groups. Similarly, there were no differences between groups in the incidence of combined cardiovascular morbidity or all-cause mortality. Conclusion: Compared with placebo, long- term use of cilostazol, 100 mg or 50 mg, twice a day significantly improves walking distances in patients with intermittent claudication.",
author = "Beebe, {Hugh G.} and Dawson, {David L} and Cutler, {Bruce S.} and Herd, {J. Alan} and Strandness, {D. Eugene} and Bortey, {Enoch B.} and Forbes, {William P.}",
year = "1999",
month = "9",
day = "27",
doi = "10.1001/archinte.159.17.2041",
language = "English (US)",
volume = "159",
pages = "2041--2050",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "17",

}

TY - JOUR

T1 - A new pharmacological treatment for intermittent claudication

T2 - Results of a randomized, multicenter trial

AU - Beebe, Hugh G.

AU - Dawson, David L

AU - Cutler, Bruce S.

AU - Herd, J. Alan

AU - Strandness, D. Eugene

AU - Bortey, Enoch B.

AU - Forbes, William P.

PY - 1999/9/27

Y1 - 1999/9/27

N2 - Background: Effective medication is limited for the relief of intermittent claudication, a common manifestation of arterial occlusive disease. Cilostazol is a potent inhibitor of platelet aggregation with vasodilation effects. Objective: To evaluate the safety and efficacy of cilostazol for the treatment of intermittent claudication. Methods: Thirty- seven outpatient vascular medicine clinics at regional tertiary and university hospitals in the United States participated in this multicenter, randomized, double-blind, placebo-controlled, parallel trial. Of the 663 screened volunteer patients with leg discomfort, a total of 516 men and women 40 years or older with a diagnosis of moderately severe chronic, stable, symptomatic intermittent claudication were randomized to receive cilostazol, 100 mg, cilostazol, 50 mg, or placebo twice a day orally for 24 weeks. Outcome measures included pain-free and maximal walking distances via treadmill testing, patient-based quality-of-life measures, global assessments by patient and physician, and cardiovascular morbidity and all-cause mortality survival analysis. Results: The clinical and statistical superiority of active treatment over placebo was evident as early as week 4, with continued improvement at all subsequent time points. After 24 weeks, patients who received cilostazol, 100 mg, twice a day had a 51% geometric mean improvement in maximal walking distance (P<.001 vs placebo); those who received cilostazol, 50 mg, twice a day had a 38% geometric mean improvement in maximal walking distance (P<.001 vs placebo). These percentages translate into an arithmetic mean increase in distance walked, from 129.7 m at baseline to 258.8 m at week 24 for the cilostazol, 100 mg, group, and from 131.5 to 198.8 m for the cilostazol, 50 mg, group. Geometric mean change for pain-free walking distance increased by 59% (P<.001) and 48% (P<.001), respectively, in the cilostazol, 100 mg, and cilostazol, 50 mg, groups. These results were corroborated by the results of subjective quality-of-life assessments, functional status, and global evaluations. Headache, abnormal stool samples or diarrhea, dizziness, and palpitations were the most commonly reported potentially drug-related adverse events and were self-limited. A total of 75 patients (14.5%) withdrew because of any adverse event, which was equally distributed between all 3 treatment groups. Similarly, there were no differences between groups in the incidence of combined cardiovascular morbidity or all-cause mortality. Conclusion: Compared with placebo, long- term use of cilostazol, 100 mg or 50 mg, twice a day significantly improves walking distances in patients with intermittent claudication.

AB - Background: Effective medication is limited for the relief of intermittent claudication, a common manifestation of arterial occlusive disease. Cilostazol is a potent inhibitor of platelet aggregation with vasodilation effects. Objective: To evaluate the safety and efficacy of cilostazol for the treatment of intermittent claudication. Methods: Thirty- seven outpatient vascular medicine clinics at regional tertiary and university hospitals in the United States participated in this multicenter, randomized, double-blind, placebo-controlled, parallel trial. Of the 663 screened volunteer patients with leg discomfort, a total of 516 men and women 40 years or older with a diagnosis of moderately severe chronic, stable, symptomatic intermittent claudication were randomized to receive cilostazol, 100 mg, cilostazol, 50 mg, or placebo twice a day orally for 24 weeks. Outcome measures included pain-free and maximal walking distances via treadmill testing, patient-based quality-of-life measures, global assessments by patient and physician, and cardiovascular morbidity and all-cause mortality survival analysis. Results: The clinical and statistical superiority of active treatment over placebo was evident as early as week 4, with continued improvement at all subsequent time points. After 24 weeks, patients who received cilostazol, 100 mg, twice a day had a 51% geometric mean improvement in maximal walking distance (P<.001 vs placebo); those who received cilostazol, 50 mg, twice a day had a 38% geometric mean improvement in maximal walking distance (P<.001 vs placebo). These percentages translate into an arithmetic mean increase in distance walked, from 129.7 m at baseline to 258.8 m at week 24 for the cilostazol, 100 mg, group, and from 131.5 to 198.8 m for the cilostazol, 50 mg, group. Geometric mean change for pain-free walking distance increased by 59% (P<.001) and 48% (P<.001), respectively, in the cilostazol, 100 mg, and cilostazol, 50 mg, groups. These results were corroborated by the results of subjective quality-of-life assessments, functional status, and global evaluations. Headache, abnormal stool samples or diarrhea, dizziness, and palpitations were the most commonly reported potentially drug-related adverse events and were self-limited. A total of 75 patients (14.5%) withdrew because of any adverse event, which was equally distributed between all 3 treatment groups. Similarly, there were no differences between groups in the incidence of combined cardiovascular morbidity or all-cause mortality. Conclusion: Compared with placebo, long- term use of cilostazol, 100 mg or 50 mg, twice a day significantly improves walking distances in patients with intermittent claudication.

UR - http://www.scopus.com/inward/record.url?scp=0033610236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033610236&partnerID=8YFLogxK

U2 - 10.1001/archinte.159.17.2041

DO - 10.1001/archinte.159.17.2041

M3 - Article

VL - 159

SP - 2041

EP - 2050

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 17

ER -